Arabic Arabic English English French French German German
dark

Vedanta Biosciences Completes $68 Million Series D Financing

Vedanta Biosciences, Inc., a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, announced the closing of a $68 million Series D financing and provided a pipeline update. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Lexaria’s DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3

Next Post

Late-Breaking Trial Data at TVT Demonstrate Sustained Safety and Performance of WATCHMAN FLX™ Left Atrial Appendage Closure Device

Related Posts
Total
0
Share